{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T03:09:32Z","timestamp":1793934572052,"version":"4.8.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jaad.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.jaad.2017.07.047","type":"journal-article","created":{"date-parts":[[2017,9,13]],"date-time":"2017-09-13T23:45:32Z","timestamp":1505346332000},"page":"838-844","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Serious infections among a large cohort of subjects with systemically treated psoriasis"],"prefix":"10.1016","volume":"77","author":[{"given":"Allison S.","family":"Dobry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles P.","family":"Quesenberry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Thomas","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie L.","family":"Geier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam M.","family":"Asgari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3 Pt 1","key":"10.1016\/j.jaad.2017.07.047_bib1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","article-title":"Psoriasis causes as much disability as other major medical diseases","volume":"41","author":"Rapp","year":"1999","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2017.07.047_bib2","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/jamadermatol.2013.5015","article-title":"Psoriasis severity and\u00a0the prevalence of major medical comorbidity: a\u00a0population-based study","volume":"149","author":"Yeung","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"suppl 2","key":"10.1016\/j.jaad.2017.07.047_bib3","doi-asserted-by":"crossref","first-page":"ii18","DOI":"10.1136\/ard.2004.033217","article-title":"Psoriasis: epidemiology, clinical features, and quality of life","volume":"64","author":"Langley","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2017.07.047_bib4","series-title":"Clinical Review of Biologic License Application STN 12507\/0 Efalizumab for Moderate to Severe Chronic Plaque Psoriasis","year":"2003"},{"key":"10.1016\/j.jaad.2017.07.047_bib5","series-title":"Final Clinical Review Biologic License Application STN BL 125036\/0 for Alefacept for Treatment of Moderate to Severe Chronic Plaque Psoriasis","year":"2003"},{"issue":"5","key":"10.1016\/j.jaad.2017.07.047_bib6","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.clindermatol.2003.08.015","article-title":"Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis","volume":"21","author":"Victor","year":"2003","journal-title":"Clin Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2017.07.047_bib7","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/bjd.14776","article-title":"Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts","volume":"176","author":"Garc\u00eda-Doval","year":"2017","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2017.07.047_bib8","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","article-title":"Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"54","author":"Dixon","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.jaad.2017.07.047_bib9","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/annrheumdis-2012-201338","article-title":"Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry","volume":"72","author":"van Dartel","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.jaad.2017.07.047_bib10","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1002\/art.21386","article-title":"Infections in patients with rheumatoid arthritis treated with biologic agents","volume":"52","author":"Listing","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.jaad.2017.07.047_bib11","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jaad.2016.07.039","article-title":"Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti-tumor necrosis factor agents versus classic therapies: prospective meta-analysis of Psonet registries","volume":"76","author":"Garcia-Doval","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2017.07.047_bib12","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","article-title":"Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"151","author":"Kalb","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2017.07.047_bib13","series-title":"Similarity of the adult Kaiser Permanente membership in Northern California to the insured and general population in Northern California: statistics from the 2007 California Health Interview Survey. Internal Division of Research Report, 2012","author":"Gordon","year":"2012"},{"issue":"6","key":"10.1016\/j.jaad.2017.07.047_bib14","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.mcna.2015.07.008","article-title":"The role of biologic therapies in dermatology","volume":"99","author":"Fathi","year":"2015","journal-title":"Med Clin North Am"},{"issue":"2","key":"10.1016\/j.jaad.2017.07.047_bib15","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/annrheumdis-2011-201108","article-title":"Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"72","author":"Galloway","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jaad.2017.07.047_bib16","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","article-title":"Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial","volume":"51","author":"Gottlieb","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"9494","key":"10.1016\/j.jaad.2017.07.047_bib17","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jaad.2017.07.047_bib18","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/j.1365-2133.2011.10615.x","article-title":"Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)","volume":"165","author":"Barker","year":"2011","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2017.07.047_bib19","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/bjd.13004","article-title":"Long-term efficacy and safety of infliximab maintenance therapy in\u00a0patients with plaque-type psoriasis in real-world practice","volume":"171","author":"Shear","year":"2014","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2017.07.047_bib20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jaad.2006.07.017","article-title":"A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis","volume":"56","author":"Menter","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2017.07.047_bib21","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/j.jid.2016.03.035","article-title":"Risk of serious infections in patients with psoriasis on biologic therapies: a systematic review and meta-analysis","volume":"136","author":"Yiu","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2017.07.047_bib22","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jaad.2010.08.036","article-title":"Increased risk of infectious disease requiring hospitalization among patients with psoriasis: a population-based cohort","volume":"65","author":"Wakkee","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2017.07.047_bib23","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1001\/archdermatol.2011.2768","article-title":"Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials","volume":"148","author":"Garcia-Doval","year":"2012","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2017.07.047_bib24","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1001\/archdermatol.2012.370","article-title":"Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting","volume":"148","author":"Gelfand","year":"2012","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2017.07.047_bib25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/ije\/dyn040","article-title":"Cohort profile: the Diabetes Study of Northern California (DISTANCE)\u2014objectives and design of a survey follow-up study of social health disparities in a managed care population","volume":"38","author":"Moffet","year":"2009","journal-title":"Int J Epidemiol"},{"issue":"6","key":"10.1016\/j.jaad.2017.07.047_bib26","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/bjd.12404","article-title":"Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2)","volume":"168","author":"Reich","year":"2013","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2017.07.047_bib27","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2165\/11587890-000000000-00000","article-title":"The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials","volume":"12","author":"Leonardi","year":"2011","journal-title":"Am J Clin Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962217321771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962217321771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T18:51:09Z","timestamp":1750877469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962217321771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0190962217321771"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2017.07.047","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serious infections among a large cohort of subjects with systemically treated psoriasis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2017.07.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}